WEBULL

BioGaia (OM:BIOG B) Stock Confronts Margin Concerns As Net Margin Reaches 22%

Simply Wall St · 2d ago

BioGaia (OM:BIOG B) has reported Q2 2026 revenue of SEK440.9 million and basic EPS of SEK1.02, with trailing twelve month EPS at SEK3.43 and revenue at SEK1.58 billion framing the latest quarter in a broader context. Over recent quarters the company has seen revenue move from SEK404.7 million and EPS of SEK0.87 in Q2 2025 to SEK440.9 million and EPS of SEK1.02 in Q2 2026, with the trailing revenue line stepping up from SEK1.44 billion and EPS of SEK2.83 at Q2 2025 to SEK1.58 billion and EPS of SEK3.43 at Q2 2026. This sets up a story of firmer margins and earnings quality that investors will be dissecting closely.

See our full analysis for BioGaia.

With the headline numbers on the table, the next step is to line these results up against the prevailing market and community narratives to see which views are supported by the data and which might need a rethink.

See what the community is saying about BioGaia

OM:BIOG B Revenue & Expenses Breakdown as at Jul 2026
OM:BIOG B Revenue & Expenses Breakdown as at Jul 2026

Margins at 22% highlight earnings quality

  • Over the last 12 months BioGaia reported a net profit of SEK347.2 million on SEK1.58b of revenue, which works out to a 22% net margin compared with 19.9% the prior year.
  • Consensus narrative points to higher operating expenses and weaker EBIT margin, yet the 22% net margin and SEK3.43 trailing EPS show that profitability at the bottom line has held up even as spending has risen.
    • EBIT margin is described as moving from 35% to 27% while net income over the trailing period is SEK347.2 million, so some of the spending is still flowing through to earnings.
    • With pediatric products still accounting for about 75 to 77% of sales, the margin profile is being sustained mainly by the existing core business rather than a fully diversified product mix.

Revenue trend and 21.1% earnings growth

  • On a trailing basis revenue is SEK1.58b and earnings growth over the past year is reported at 21.1%, alongside trailing EPS of SEK3.43 that frames Q2’s SEK1.02 EPS within a stronger 12 month picture.
  • Analysts' consensus view ties this 21.1% earnings growth to drivers like adult health segment momentum and direct sales expansion, but also flags risks from higher operating expenses and slower EMEA performance.
    • Adult health is cited as growing 23% net of currency effects and direct business now represents 36% of sales, which fits with the stronger trailing earnings figure.
    • At the same time, operating expenses are said to have risen 25% year over year and cash from operations declined 35%, which shows the higher growth rate has come with heavier spending and softer cash conversion.

BioGaia valuation at 36.4x P/E

  • BioGaia trades on a 36.4x P/E with a share price of SEK124.80, against a DCF fair value of SEK183.48 and an analyst price target of SEK165.00, while the European Biotechs industry average P/E is 16.1x.
  • Consensus narrative highlights growth in adult and North American channels as a support for this higher multiple, yet the mix of a 3.21% dividend that is not well covered by free cash flow and a P/E above the industry average leaves limited room if growth slows.
    • The stock is described as trading about 32% below the DCF fair value, but the P/E is still more than double the 16.1x industry average even though BioGaia’s net margin is 22%.
    • Bears focus on the 25% rise in operating expenses and the drop in EBIT margin to 27%, which, together with lower cash flow from operations and a cash balance of SEK622 million, add pressure to sustain both growth and the dividend.
For a deeper context on how these profit and growth trends fit into the bigger story around BioGaia, and to see how bulls frame the upside case after this set of numbers, 🐂 BioGaia Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for BioGaia on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this BioGaia update leaves you weighing both the risks and the upside, do not wait to test the numbers yourself and stress test your view against the 3 key rewards and 1 important warning sign.

See What Else Is Out There

BioGaia combines a 36.4x P/E, a dividend not well covered by free cash flow, higher operating expenses and softer cash conversion, which puts pressure on sustainability.

If those BioGaia pressure points make you want more income resilience in your portfolio, test your ideas against our 470 dividend fortresses while the market is still digesting these results.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.